Some new insights in intestinal failure-associated liver disease

Abstract

It is likely that this reversal involves several factors such as the change in n-6: n-3 ratio, the reduction in phytosterol load, the increased provision of alpha-tocopherol as antioxidant agent. Alternative issue might be based on the use of a new generation of ILE aiming to provide n-3 and to reduce n-6 fatty acids load while enhancing alpha-tocopherol intake. New data are based on the use of an ILE containing a balanced proportion of four types of oil as a physical mixture of 30% soybean oil, 30% medium-chain triglycerides, 25% olive oil and 15% fish oil with amounts of alpha-tocopherol calculated according to the number of double bonds. This new emulsion was reported to be beneficial in reversing or preventing liver disease.

Intestinal Transplant Registry Report: Global Activity and Trends

“…This change is likely a result of the improved ability of specialized, interdisciplinary intestine failure units to prevent or resolve intestinal failure associated liver disease (IFALD) which has diminished demand (11,(19)(20)(21)(22)(23)(24)(25)(26)(27)(28)(29). It is unlikely that this change is due to a deficiency in case reporting since (1) a similar trend is documented in the most recent Scientific Registry of Transplant Recipients 2011 Annual Report for the Intestine (http://srtr.transplant.hrsa.…”

Outcome on home parenteral nutrition for benign intestinal failure: A review of the literature and benchmarking with the European prospective survey of ESPEN

“…The use of lipid emulsion with a low content of omega-6 fatty acids is recommended both in preventing and treating IF/ PNALD. 107 Progression of IF/PNALD to liver failure represents the greatest concern in terms of potential mortality for the long-term HPN patient. The risk of development of liver failure appears to be higher in children, specifically very young children, than in adults.…”

Teduglutide, a novel glucagon-like peptide 2 analog, in the treatment of patients with short bowel syndrome

“…Poor catheter care technique, insertion site-, tunnel-and catheterrelated bloodstream infections may lead to bacteremia and even septicemia, and the presence of a central catheter may lead to central venous thrombosis and, on occasion, embolism [Buchman et al 2003]. In addition, constituents of the parenteral solutions and chronic dehydration may contribute to progressive intestinal failure associated liver and renal disease, and eventually organ failure [Goulet et al 2009;Lauverjat et al 2006]. Together, the symptoms of SBS-IF, that is, diarrhea, large stomal output, stomal problems, fear of fecal incontinence, meteorism, abdominal pain, and the inconvenience and complications related to PS may cause potential restrictions in the lifestyle of patients and may lead to significant impairment of their quality of life [Jeppesen et al 1999b;Baxter et al 2006].…”